ClinicalTrials.gg
CompletedNCT02616861Updated Apr 3, 2019

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

A Phase 1 interventional study of IW-1973 and Matching Placebo Tablet in Healthy, sponsored by Cyclerion Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-03.

Sponsored by Cyclerion Therapeutics (formerly part of Ironwood Pharmaceuticals, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of the IW-1973 Tablet administered orally to healthy volunteers, in fed and fasted states, in a single-dose crossover study.

Stage 2: To assess the safety, tolerability, PK profile, and PD effects of a range of doses of IW-1973 Tablet administered orally to healthy subjects in a 21-day, multiple ascending-dose study with optional up-titration of dose level within cohort.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Cyclerion Therapeutics is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an ambulatory male or female between 18 and 55 years old at the Screening Visit
  • Subject's score is > 18.5 and \< 30.0 kg/m2 at the Screening Visit
  • Women of must have a negative pregnancy test and must agree to use double-barrier
  • Subject is in good health and has no findings on a physical examination
  • Other inclusion criteria per protocol

Exclusion criteria

Exclusion Criteria:

  • History of any medical condition
  • Other exclusion criteria per protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    IW-1973

    1973 Escalating Doses

    Drug: IW-1973

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Matching Placebo Tablet

Interventions

  • IW-1973 Tablet

  • DrugMatching Placebo Tablet

    Matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events

    Time frame: 42 Days

  2. Maximum observed plasma concentration (Cmax)

    Time frame: 42 Days

  3. Blood Pressure

    Time frame: 42 days

  4. Area under the plasma concentration time curve during a dosing interval (AUC)

    Time frame: 42 Days

  5. Time of maximum observed plasma concentration (Tmax)

    Time frame: 42 Days

  6. Heart rate

    Time frame: 42 Days

  7. Serum cGMP

    Time frame: 42 Days

07

Study locations

1 site
  • Ironwood Investigator
    San Antonio, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2015
First posted
Nov 30, 2015
Start
Nov 2015
Primary completionActual
May 2016
CompletionActual
Jun 2016
Last update
Apr 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02616861
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Nov 2015
Primary completion
May 2016
Completion
Jun 2016
Last update
Apr 3, 2019

Study contacts

John Hanrahan, MD
study director · Ironwood Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Praliciguat

Start the discussion